期刊文献+

前列地尔联合缬沙坦治疗早期糖尿病肾病的效果观察 被引量:11

下载PDF
导出
摘要 目的观察前列地尔与缬沙坦联合应用治疗早期糖尿病肾病的临床效果。方法将60例确诊早期糖尿病肾病的患者随机分为实验组和对照组,实验组予前列地尔静脉滴注联合缬沙坦口服,对照组单用缬沙坦,两组均给予糖尿病基础治疗,比较两组治疗前后血压及尿蛋白排出量的变化情况。结果两组患者血压均控制理想,24 h尿蛋白量均有下降,以实验组下降最明显,两组间差异有统计学意义(P<0.05)。结论前列地尔与缬沙坦联合应用控制早期糖尿病肾病患者尿蛋白排出量及血压的效果明显优于缬沙坦单药应用的效果,两者可发挥协同作用,更大程度地保护肾脏,延缓肾功能恶化。
作者 张青
出处 《中国实用医药》 2013年第14期161-162,共2页 China Practical Medicine
  • 相关文献

参考文献6

二级参考文献24

  • 1刘振平,潘长玉.低蛋白饮食与糖尿病肾病[J].国外医学(内科学分册),1993,20(8):351-352. 被引量:8
  • 2叶山东,胡远峰.限制蛋白质摄入对糖尿病肾病的作用[J].上海医学,1993,16(4):243-245. 被引量:4
  • 3Ceriello A.New insights on oxidative stress and diabetic complications may lead to"causal"antioxidant therapy[J].Diabetes Care,2003,26(5):1589-1596.
  • 4Body-White J,Williams JC.Effect of cross-linking on matrixperme ability:a model for AGE2 modified basementmembranes[J].Kidney Int,1996,46(3):348-353.
  • 5Karamanos B,Porta M,Songini M,et al.Different risk factors of microangiopathy in patients with type 1 diabetes mellitus of shorter long duration:the Eurodiab IDDM Comp lications Study[J].Diabetologia,2000,43(3):348-355.
  • 6Barroso LC,Herrera ND,Hueros JC.et al.lncidence of cardiovascular disease and vajidity of equations of coronary risk in diabeticpatients with metabolic syndrome[J].Med Clin(Barc),2007,128(14):529-535.
  • 7No authors listed.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKFDS 391UK Prospective Diabetes Study Group[J],BMJ,1998,317(7160):713-720.
  • 8Dai C,Stolz DB,Bastacky SI,et al.Essential role of integrinlinkedkinase in podocyte biology:bridging the Integrin and slit diaphragm signaling[J].J Am Soc Nephrol,2006.17(8):2164-2175.
  • 9Kim SI,Kwak JH.Zachariah M.et al.TGF2-activated kinase 1 andTAK 1-binding protein 1 cooperate to mediate TGF212 inducedMKK32p38 MAPK activation and stimulation of type Ⅰ collagen[J].AmJ Physiol Renal Physiol,2007,292(5):1471-1478.
  • 10Huang CC,J inn YG,Shyi JS,et al.Insulin and heparin suppress peroxide production in diabetic ratglomeruli stimulated with low-density Lipoprotein[J].Kidney Int,2001,59(1):124-130.

共引文献305

同被引文献65

  • 1曹雪莹,汤力,魏日胞.前列地尔治疗糖尿病肾病蛋白尿的临床观察[J].中国实用医药,2007,2(7):36-38. 被引量:21
  • 2高璐,于德民.马来酸罗格列酮对早期糖尿病肾病患者尿白蛋白排泄的影响[J].中国慢性病预防与控制,2007,15(2):126-128. 被引量:3
  • 3李嘉雯.糖尿病肾病临床治疗分析[J].医药前沿,2013,14(3):212.
  • 4Reidy K, Kang HM, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease[J]. J Clin Invest, 2014,124(6):2333-2340.
  • 5Wang H, Deng JL, Yue J, et al. Prostaglandin E1 for preventing the progression of diabetic kidney disease[J]. Cochrane Database Syst Rev, 2010,(5):CD006872.
  • 6Nixon RM, Muller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach[J]. Int J Clin Pract, 2009,63(5):766-775.
  • 7Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure[J]. Adv Ther, 2010,27(5):257-284.
  • 8Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium[J]? Diabetologia, 2008,51(5):714-725.
  • 9Christou GA,Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria[J]. J Endocrinol, 2014,221(2):R49-R61.
  • 10Kreutz RP, Nystrom P, Kreutz Y, et al. Inhibition of platelet aggregation by prostaglandin E1(PGE1)in diabetic patients during therapy with clopidogrel and aspirin[J]. Platelets, 2013,24(2):145-150.

引证文献11

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部